Ecovyst Reports Second Quarter 2025 Results
Second Quarter 2025 Results & Highlights
- Sales of
$200.1 million , compared to$182.8 million in the second quarter of 2024 - Net Income of
$6.0 million , compared to$8.3 million in the year-ago quarter, with a net income margin of 3.0% and diluted net income per share of$0.05 . Adjusted Net Income was$13.7 million with Adjusted Diluted Income per share of$0.12 - Adjusted EBITDA of
$55.7 million , compared to$56.9 million in the second quarter of 2024, with an Adjusted EBITDA margin of 24.4% - Cash flows from operating activities were
$43.3 million for the six months endedJune 30, 2025 , compared to$46.4 million for the six months endedJune 30, 2024 . Adjusted Free Cash Flow was$(2.4) million for the six months endedJune 30, 2025 , compared to$14.4 million for the six months endedJune 30, 2024 - Completed the acquisition of the
Waggaman, Louisiana sulfuric acid production assets fromCornerstone Chemical Company for$35.0 million and customary working capital adjustments of$6.3 million - Repurchased
$21.9 million of common stock
"We are pleased with our results for the second quarter of 2025. With demand fundamentals generally in line with our expectations, we delivered Adjusted EBITDA of
"During the second quarter we completed the acquisition of the
Review of Segment Results and Business Trends
Second quarter 2025 sales for
Advanced Materials & Catalysts
During the second quarter of 2025, Advanced Silicas sales were
Cash Flows and Balance Sheet
Cash flows from operating activities was
2025 Financial Outlook
We are maintaining the midpoint of our full-year 2025 Adjusted EBITDA guidance range while tightening the range to reflect results for the first half of the year, and expectations for the balance of the year. In addition, we are increasing the sales guidance range to reflect factors including the acquisition of the
"Regarding tariffs, proposed tariff levels are still subject to change, and there remains the possibility of incremental demand disruption related to tariffs. Nevertheless, as mentioned in our first quarter earnings call, we maintain the view that the direct impact of current tariffs is limited to approximately
The Company's current guidance for full year 2025 is as follows:
- Sales of
$795 million to$835 million 1 (change from$785 million to$845 million ) - Sales of
$125 million to$140 million for proportionate 50% share of Zeolyst Joint Venture, which is excluded from GAAP Sales (change from$115 million to$130 million ) - Adjusted EBITDA2 of
$242 million to$254 million (change from$238 million to$258 million ) - Adjusted Free Cash Flow2 of
$70 million to$80 million (change from$60 million to$80 million ) - Capital expenditures of
$80 million to$90 million - Interest expense of
$46 million to$50 million (change from$47 million to$53 million ) - Depreciation & Amortization
Ecovyst -$92 million to$98 million (change from$87 million to$93 million )- Zeolyst J.V. -
$12 million to$14 million
- Effective tax rate in the mid 20% range
- Adjusted Net Income2 of
$60 million to$80 million , with Adjusted Diluted Income2 per share of$0.52 to$0.68 (change from$58 million to$85 million and$0.50 to$0.70 )
The Company's guidance for the third quarter of 2025 is as follows:
- Adjusted EBITDA2 of
$62 million to$72 million
1Sales outlook for 2025 assumes higher average sulfur prices compared to 2024 and higher projected pass-through of sulfur costs of approximately
2In reliance upon the unreasonable efforts exemption provided under Item 10(e)(1)(i)(B) of Regulation S-K, the Company is not able to provide a reconciliation of its non-GAAP financial guidance to the corresponding GAAP measures without unreasonable effort because of the inherent difficulty in forecasting and quantifying certain amounts necessary for such a reconciliation such as certain non-cash, nonrecurring or other items that are included in net income and net cash provided by operating activities as well as the related tax impacts of these items and asset dispositions / acquisitions and changes in foreign currency exchange rates that are included in cash flow, due to the uncertainty and variability of the nature and amount of these future charges and costs. Because this information is uncertain, the Company is unable to address the probable significance of the unavailable information, which could be material to future results.
Stock Repurchase
In
During the second quarter of 2025, the Company repurchased 2,926,152 shares of its common stock on the open market at an average price of
During the second quarter of 2024, the Company repurchased 552,081 shares of its common stock on the open market at an average price of
For possible future repurchases, the actual timing, number, and nature of shares repurchased will depend on a variety of factors, including stock price, trading volume, and general business and market conditions and may be conducted through negotiated transactions, open market repurchases or other means, including through Rule 10b-18 and Rule 10b5-1 trading plans or accelerated share repurchases. The repurchase program does not obligate the Company to acquire any number of shares in any specific period, or at all, and the repurchase program may be amended, suspended or discontinued at any time at the Company's discretion.
Conference Call and Webcast Details
On
Conference Call: Investors may listen to the conference call live via telephone by dialing 1 (800) 245-3047 (domestic) or
1 (203) 518-9765 (international) and use the participant code ECVTQ225.
Webcast: An audio-only live webcast of the conference call and presentation materials can be accessed at https://investor.ecovyst.com. A replay of the conference call/webcast will be made available at https://investor.ecovyst.com/events-presentations.
Investor Contact:
(484) 617-1225
gene.shiels@ecovyst.com
About
We have two uniquely positioned specialty businesses:
Presentation of Non-GAAP Financial Measures
In addition to the results provided in accordance with
Zeolyst Joint Venture
The Company's zeolite catalysts product group operates through its Zeolyst Joint Venture, which is accounted for as an equity method investment in accordance with GAAP. The presentation of the Zeolyst Joint Venture's sales represents 50% of the sales of the Zeolyst Joint Venture. The Company does not record its proportionate share of sales from the Zeolyst Joint Venture accounted for using the equity method as revenue and such sales are not consolidated within its results of operations. However, Adjusted EBITDA for the Company's Advanced Materials & Catalysts segment reflects the Company's 50% portion of the earnings from the Zeolyst Joint Venture that have been recorded as equity in net income in the Company's condensed consolidated statements of income for such periods and includes Zeolyst Joint Venture adjustments on a proportionate basis based on the Company's 50% ownership interest. Accordingly, the Company's Adjusted EBITDA margins are calculated including 50% of the sales of the Zeolyst Joint Venture for the relevant periods in the denominator.
Note on Forward-Looking Statements
Some of the information contained in this press release constitutes "forward-looking statements." Forward-looking statements can be identified by words such as "anticipates," "intends," "plans," "seeks," "believes," "estimates," "expects," "projects" and similar references to future periods. Forward-looking statements are based on our current expectations and assumptions regarding our business, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. Examples of forward-looking statements include, but are not limited to, statements regarding our future results of operations, financial condition, capital expenditure projects, liquidity, prospects, growth, strategies, capital allocation program (including the stock repurchase program), product and service offerings, expected demand trends, the timing and outcome, if any, of our strategic review process for our Advanced Materials & Catalysts segment, the impact of the acquisition of the
CONDENSED CONSOLIDATED STATEMENTS OF INCOME (in millions, except share and per share amounts) |
||||||||||||
|
||||||||||||
|
|
Three months ended
|
|
|
|
Six months ended
|
|
|
||||
|
|
2025 |
|
2024 |
|
% Change |
|
2025 |
|
2024 |
|
% Change |
|
|
|
||||||||||
Sales |
|
$ 200.1 |
|
$ 182.8 |
|
9.5 % |
|
$ 362.3 |
|
$ 343.4 |
|
5.5 % |
Cost of goods sold |
|
150.4 |
|
129.1 |
|
16.5 % |
|
287.0 |
|
250.5 |
|
14.6 % |
Gross profit |
|
49.7 |
|
53.7 |
|
(7.4) % |
|
75.3 |
|
92.9 |
|
(18.9) % |
Selling, general and administrative expenses |
|
22.7 |
|
22.7 |
|
— % |
|
44.0 |
|
44.3 |
|
(0.7) % |
Other operating expense, net |
|
9.2 |
|
3.1 |
|
196.8 % |
|
14.4 |
|
6.8 |
|
111.8 % |
Operating income |
|
17.8 |
|
27.9 |
|
(36.2) % |
|
16.9 |
|
41.8 |
|
(59.6) % |
Equity in net (income) from affiliated companies |
|
(1.9) |
|
(1.4) |
|
35.7 % |
|
(10.8) |
|
(3.5) |
|
208.6 % |
Interest expense, net |
|
11.1 |
|
12.9 |
|
(14.0) % |
|
22.1 |
|
26.3 |
|
(16.0) % |
Debt modification and extinguishment costs |
|
— |
|
4.6 |
|
(100.0) % |
|
1.0 |
|
4.6 |
|
(78.3) % |
Other expense, net |
|
0.6 |
|
0.4 |
|
50.0 % |
|
0.7 |
|
0.6 |
|
16.7 % |
Income before income taxes |
|
8.0 |
|
11.4 |
|
(29.8) % |
|
3.9 |
|
13.8 |
|
(71.7) % |
Provision for income taxes |
|
2.0 |
|
3.1 |
|
(35.5) % |
|
1.5 |
|
4.3 |
|
(65.1) % |
Effective tax rate |
|
25.6 % |
|
27.1 % |
|
|
|
38.8 % |
|
30.9 % |
|
|
Net income |
|
$ 6.0 |
|
$ 8.3 |
|
(27.7) % |
|
$ 2.4 |
|
$ 9.5 |
|
(74.7) % |
|
|
|
|
|
|
|
|
|
|
|
|
|
Earnings per share: |
|
|
|
|
|
|
|
|
|
|
|
|
Basic earnings per share |
|
$ 0.05 |
|
$ 0.07 |
|
|
|
$ 0.02 |
|
$ 0.08 |
|
|
Diluted earnings per share |
|
$ 0.05 |
|
$ 0.07 |
|
|
|
$ 0.02 |
|
$ 0.08 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted average shares outstanding: |
|
|
|
|
|
|
|
|
|
|
|
|
Basic |
|
116,232,528 |
|
116,912,332 |
|
|
|
116,745,476 |
|
116,935,708 |
|
|
Diluted |
|
116,535,060 |
|
117,635,289 |
|
|
|
117,044,461 |
|
117,545,240 |
|
|
CONDENSED CONSOLIDATED BALANCE SHEETS (in millions, except share and per share amounts) |
|||
|
|||
|
|
|
|
ASSETS |
|
|
|
Cash and cash equivalents |
$ 69.6 |
|
$ 146.0 |
Accounts receivable, net |
103.5 |
|
77.9 |
Inventories, net |
66.9 |
|
57.1 |
Derivative assets |
4.0 |
|
6.5 |
Prepaid and other current assets |
25.4 |
|
16.1 |
Total current assets |
269.4 |
|
303.6 |
Investments in affiliated companies |
346.5 |
|
349.3 |
Property, plant and equipment, net |
602.9 |
|
569.3 |
|
406.7 |
|
404.1 |
Other intangible assets, net |
94.8 |
|
98.4 |
Right-of-use lease assets |
37.1 |
|
33.6 |
Other long-term assets |
39.0 |
|
44.0 |
Total assets |
$ 1,796.4 |
|
$ 1,802.3 |
LIABILITIES |
|
|
|
Current maturities of long-term debt |
$ 8.7 |
|
$ 8.7 |
Accounts payable |
47.9 |
|
43.9 |
Operating lease liabilities—current |
9.0 |
|
9.3 |
Accrued liabilities |
54.0 |
|
53.2 |
Total current liabilities |
119.6 |
|
115.1 |
Long-term debt, excluding current portion |
847.9 |
|
852.1 |
Deferred income taxes |
104.6 |
|
105.4 |
Operating lease liabilities—noncurrent |
28.2 |
|
24.2 |
Other long-term liabilities |
3.7 |
|
5.0 |
Total liabilities |
1,104.0 |
|
1,101.8 |
Commitments and contingencies |
|
|
|
EQUITY |
|
|
|
Common stock ( |
1.4 |
|
1.4 |
Preferred stock ( |
— |
|
— |
Additional paid-in capital |
1,103.5 |
|
1,106.8 |
Accumulated deficit |
(175.1) |
|
(177.5) |
|
(236.6) |
|
(222.8) |
Accumulated other comprehensive loss |
(0.8) |
|
(7.4) |
Total equity |
692.4 |
|
700.5 |
Total liabilities and equity |
$ 1,796.4 |
|
$ 1,802.3 |
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS |
|||
|
|||
|
Six months ended
|
||
|
2025 |
|
2024 |
Cash flows from operating activities: |
(in millions) |
||
Net income |
$ 2.4 |
|
$ 9.5 |
Adjustments to reconcile net income to net cash provided by operating activities: |
|
|
|
Depreciation |
40.0 |
|
36.5 |
Amortization |
7.0 |
|
7.0 |
Amortization of deferred financing costs and original issue discount |
0.7 |
|
1.1 |
Debt extinguishment costs |
— |
|
0.1 |
Foreign currency exchange loss |
0.4 |
|
0.2 |
Deferred income tax provision (benefit) |
1.4 |
|
(1.7) |
Net loss on asset disposals |
0.4 |
|
0.6 |
Stock compensation |
6.5 |
|
7.5 |
Equity in net (income) from affiliated companies |
(10.8) |
|
(3.5) |
Dividends received from affiliated companies |
20.0 |
|
33.0 |
Other, net |
(0.1) |
|
2.3 |
Working capital changes that provided (used) cash: |
|
|
|
Receivables |
(15.0) |
|
(4.1) |
Inventories |
(6.0) |
|
(6.7) |
Prepaids and other current assets |
(2.5) |
|
(4.5) |
Accounts payable |
6.5 |
|
(3.3) |
Accrued liabilities |
(7.6) |
|
(27.6) |
Net cash provided by operating activities |
43.3 |
|
46.4 |
|
|
|
|
Cash flows from investing activities: |
|
|
|
Purchases of property, plant and equipment |
(49.5) |
|
(36.6) |
Business combinations |
(41.3) |
|
— |
Other, net |
— |
|
(0.2) |
Net cash used in investing activities |
(90.8) |
|
(36.8) |
|
|
|
|
Cash flows from financing activities: |
|
|
|
Issuance of long-term debt, net of original issue discount and financing fees |
870.8 |
|
870.8 |
Repayments of long-term debt |
(875.2) |
|
(877.5) |
Repurchases of common shares |
(21.9) |
|
(5.0) |
Tax withholdings on equity award vesting |
(1.5) |
|
(1.2) |
Repayment of financing obligation |
(1.6) |
|
(1.5) |
Net cash used in financing activities |
(29.4) |
|
(14.4) |
|
|
|
|
Effect of exchange rate changes on cash and cash equivalents |
0.5 |
|
(0.3) |
Net change in cash and cash equivalents |
(76.4) |
|
(5.1) |
Cash and cash equivalents at beginning of period |
146.0 |
|
88.4 |
Cash and cash equivalents at end of period |
$ 69.6 |
|
$ 83.3 |
Appendix Table A-1: Reconciliation of Net Income (Loss) to Adjusted EBITDA |
||||||||
|
||||||||
|
|
Three months ended
|
|
Six months ended
|
||||
|
|
2025 |
|
2024 |
|
2025 |
|
2024 |
|
|
(in millions) |
||||||
Reconciliation of net income to Adjusted EBITDA |
|
|
|
|
|
|
|
|
Net income |
|
$ 6.0 |
|
$ 8.3 |
|
$ 2.4 |
|
$ 9.5 |
Provision for income taxes |
|
2.0 |
|
3.1 |
|
1.5 |
|
4.3 |
Interest expense, net |
|
11.1 |
|
12.9 |
|
22.1 |
|
26.3 |
Depreciation and amortization |
|
23.9 |
|
21.6 |
|
47.1 |
|
43.6 |
EBITDA |
|
43.0 |
|
45.9 |
|
73.1 |
|
83.7 |
Joint venture depreciation, amortization and interest(a) |
|
3.2 |
|
3.2 |
|
6.3 |
|
6.5 |
Amortization of investment in affiliate step-up(b) |
|
0.6 |
|
0.9 |
|
1.2 |
|
2.5 |
Debt modification and extinguishment costs |
|
— |
|
4.6 |
|
1.0 |
|
4.6 |
Net loss on asset disposals(d) |
|
0.3 |
|
— |
|
0.4 |
|
0.6 |
Foreign currency exchange (gain) loss(e) |
|
— |
|
(0.1) |
|
0.1 |
|
0.1 |
LIFO benefit(f) |
|
(0.4) |
|
(1.5) |
|
(1.2) |
|
(2.7) |
Transaction and other related costs(g) |
|
2.7 |
|
0.1 |
|
4.5 |
|
0.2 |
Equity-based compensation |
|
3.4 |
|
3.8 |
|
6.5 |
|
7.5 |
Restructuring, integration and business optimization expenses(h) |
|
1.0 |
|
0.2 |
|
1.2 |
|
0.4 |
Other(i) |
|
1.9 |
|
(0.2) |
|
1.5 |
|
(1.0) |
Adjusted EBITDA |
|
$ 55.7 |
|
$ 56.9 |
|
$ 94.6 |
|
$ 102.4 |
|
|
Trailing twelve months ended |
||
|
|
2025 |
|
2024 |
|
|
(in millions) |
||
Reconciliation of net (loss) income to Adjusted EBITDA |
|
|
|
|
Net (loss) income |
|
$ (13.8) |
|
$ 56.1 |
(Benefit) provision for income taxes |
|
(1.3) |
|
5.4 |
Interest expense, net |
|
45.2 |
|
52.0 |
Depreciation and amortization |
|
92.8 |
|
86.9 |
EBITDA |
|
122.9 |
|
200.4 |
Joint venture depreciation, amortization and interest(a) |
|
13.2 |
|
13.1 |
Amortization of investment in affiliate step-up(b) |
|
2.4 |
|
5.7 |
Impairment of investment in affiliated companies(c) |
|
65.0 |
|
— |
Intangible asset impairment charge |
|
3.9 |
|
— |
Debt modification and extinguishment costs |
|
1.0 |
|
4.6 |
Net loss on asset disposals(d) |
|
2.3 |
|
2.4 |
Foreign currency exchange gain(e) |
|
(0.2) |
|
— |
LIFO benefit(f) |
|
(0.8) |
|
(1.6) |
Transaction and other related costs(g) |
|
4.8 |
|
0.6 |
Equity-based compensation |
|
13.0 |
|
14.4 |
Restructuring, integration and business optimization expenses(h) |
|
1.7 |
|
1.0 |
Other(i) |
|
1.1 |
|
(0.5) |
Adjusted EBITDA |
|
$ 230.3 |
|
$ 240.1 |
Descriptions to Ecovyst Non-GAAP Reconciliations
(a) |
We use Adjusted EBITDA as a performance measure to evaluate our financial results. Because our Advanced Materials & |
(b) |
Represents the amortization of the fair value adjustments associated with the equity affiliate investment in the Zeolyst Joint |
(c) |
Represents fair value impairments associated with the equity affiliate investment in the Zeolyst Joint Venture. During the |
(d) |
When asset disposals occur, we remove the impact of net gain/loss of the disposed asset because such impact primarily |
(e) |
Reflects the exclusion of the foreign currency transaction gains and losses in the condensed consolidated statements of |
(f) |
Represents non-cash adjustments to the Company's LIFO reserves for certain inventories in the |
(g) |
Relates to certain transaction costs, including debt financing, due diligence and other costs related to transactions that are |
(h) |
Includes the impact of restructuring, integration and business optimization expenses, which are incremental costs that are |
(i) |
Other consists of adjustments for items that are not core to our ongoing business operations. These adjustments include |
Appendix Table A-2: Reconciliation of Net Income and EPS to Adjusted Net Income and Adjusted EPS(1) |
|||||||||||
|
|||||||||||
|
Three months ended |
||||||||||
|
2025 |
|
2024 |
||||||||
|
Pre-tax |
Tax |
After-tax |
Per share, |
Per share, |
|
Pre-tax |
Tax |
After-tax |
Per share, |
Per share, |
|
(in millions, except share and per share amounts) |
||||||||||
Net income |
$ 8.0 |
$ 2.0 |
$ 6.0 |
$ 0.05 |
$ 0.05 |
|
$ 11.4 |
$ 3.1 |
$ 8.3 |
$ 0.07 |
$ 0.07 |
Amortization of investment |
0.6 |
0.1 |
0.5 |
— |
— |
|
0.9 |
0.2 |
0.7 |
0.01 |
0.01 |
Debt modification and |
— |
— |
— |
— |
— |
|
4.6 |
1.2 |
3.4 |
0.03 |
0.03 |
Net loss on asset disposals(d) |
0.3 |
0.1 |
0.2 |
— |
— |
|
— |
— |
— |
— |
— |
Foreign currency exchange |
— |
— |
— |
— |
— |
|
(0.1) |
— |
(0.1) |
— |
— |
LIFO benefit(f) |
(0.4) |
(0.1) |
(0.3) |
— |
— |
|
(1.5) |
(0.3) |
(1.2) |
(0.01) |
(0.01) |
Transaction and other related costs(g) |
2.7 |
0.6 |
2.1 |
0.02 |
0.02 |
|
0.1 |
— |
0.1 |
— |
— |
Equity-based compensation |
3.4 |
0.4 |
3.0 |
0.03 |
0.03 |
|
3.8 |
0.9 |
2.9 |
0.02 |
0.02 |
Restructuring, integration |
1.0 |
0.2 |
0.8 |
0.01 |
0.01 |
|
0.2 |
0.1 |
0.1 |
— |
— |
Other(i) |
1.9 |
0.5 |
1.4 |
0.01 |
0.01 |
|
(0.2) |
(0.1) |
(0.1) |
— |
— |
Adjusted Net Income(1) |
$ 17.5 |
$ 3.8 |
$ 13.7 |
$ 0.12 |
$ 0.12 |
|
$ 19.2 |
$ 5.1 |
$ 14.1 |
$ 0.12 |
$ 0.12 |
|
|
|
|
|
|
|
|
|
|
|
|
Weighted average shares |
|
|
|
116,232,528 |
116,535,060 |
|
|
|
|
116,912,332 |
117,635,289 |
|
|
|
|
|
|
|
|
|
|
|
|
|
Six months ended |
||||||||||
|
2025 |
|
2024 |
||||||||
|
Pre-tax |
Tax |
After-tax |
Per share, |
Per share, |
|
Pre-tax |
Tax |
After-tax |
Per share, |
Per share, |
|
(in millions, except share and per share amounts) |
||||||||||
Net income |
$ 3.9 |
$ 1.5 |
$ 2.4 |
$ 0.02 |
$ 0.02 |
|
$ 13.8 |
$ 4.3 |
$ 9.5 |
$ 0.08 |
$ 0.08 |
Amortization of investment |
1.2 |
0.3 |
0.9 |
0.01 |
0.01 |
|
2.5 |
0.6 |
1.9 |
0.02 |
0.02 |
Debt modification and |
1.0 |
0.2 |
0.8 |
0.01 |
0.01 |
|
4.6 |
1.2 |
3.4 |
0.03 |
0.03 |
Net loss on asset disposals(d) |
0.4 |
0.1 |
0.3 |
— |
— |
|
0.6 |
0.1 |
0.5 |
— |
— |
Foreign currency exchange |
0.1 |
— |
0.1 |
— |
— |
|
0.1 |
— |
0.1 |
— |
— |
LIFO benefit(f) |
(1.2) |
(0.3) |
(0.9) |
(0.01) |
(0.01) |
|
(2.7) |
(0.7) |
(2.0) |
(0.02) |
(0.02) |
Transaction and other related costs(g) |
4.5 |
1.1 |
3.4 |
0.03 |
0.03 |
|
0.2 |
0.1 |
0.1 |
— |
— |
Equity-based compensation |
6.5 |
0.3 |
6.2 |
0.05 |
0.05 |
|
7.5 |
1.4 |
6.1 |
0.05 |
0.05 |
Restructuring, integration |
1.2 |
0.3 |
0.9 |
0.01 |
0.01 |
|
0.4 |
0.1 |
0.3 |
— |
— |
Other(i) |
1.5 |
0.4 |
1.1 |
0.01 |
0.01 |
|
(1.0) |
(0.3) |
(0.7) |
— |
— |
Adjusted Net Income(1) |
$ 19.1 |
$ 3.9 |
$ 15.2 |
$ 0.13 |
$ 0.13 |
|
$ 26.0 |
$ 6.8 |
$ 19.2 |
$ 0.16 |
$ 0.16 |
|
|
|
|
|
|
|
|
|
|
|
|
Weighted average shares |
|
|
|
116,745,476 |
117,044,461 |
|
|
|
|
116,935,708 |
117,545,240 |
See Appendix Table A-1 for Descriptions to Ecovyst Non-GAAP Reconciliations in the table above.
(1) |
We define Adjusted Net Income as net income adjusted for non-operating income or expense and the impact of certain non- |
The adjustments to net income are shown net of applicable tax rates of 23.8% and 25.1% for the six months ended
Appendix Table A-3: Sales and Adjusted EBITDA by Business Segment |
||||||||||||
|
||||||||||||
|
|
Three months ended
|
|
|
|
Six months ended
|
|
|
||||
|
|
2025 |
|
2024 |
|
% Change |
|
2025 |
|
2024 |
|
% Change |
|
|
|
||||||||||
Sales: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 176.0 |
|
$ 153.9 |
|
14.4 % |
|
$ 319.1 |
|
$ 295.6 |
|
7.9 % |
Advanced Materials & Catalysts(1) |
|
24.1 |
|
28.9 |
|
(16.6) % |
|
43.2 |
|
47.8 |
|
(9.6) % |
Total sales |
|
$ 200.1 |
|
$ 182.8 |
|
9.5 % |
|
$ 362.3 |
|
$ 343.4 |
|
5.5 % |
|
|
|
|
|
|
|
|
|
|
|
|
|
Zeolyst Joint Venture sales |
|
$ 28.4 |
|
$ 29.0 |
|
(2.1) % |
|
$ 66.2 |
|
$ 52.5 |
|
26.1 % |
|
|
|
|
|
|
|
|
|
|
|
|
|
Adjusted EBITDA: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 49.8 |
|
$ 49.7 |
|
0.2 % |
|
$ 78.3 |
|
$ 91.2 |
|
(14.1) % |
Advanced Materials & Catalysts |
|
13.7 |
|
14.7 |
|
(6.8) % |
|
31.2 |
|
25.8 |
|
20.9 % |
Unallocated corporate expenses |
|
(7.8) |
|
(7.5) |
|
(4.0) % |
|
(14.9) |
|
(14.6) |
|
(2.1) % |
Total Adjusted EBITDA |
|
$ 55.7 |
|
$ 56.9 |
|
(2.1) % |
|
$ 94.6 |
|
$ 102.4 |
|
(7.6) % |
|
|
|
|
|
|
|
|
|
|
|
|
|
Adjusted EBITDA Margin: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
28.3 % |
|
32.3 % |
|
|
|
24.5 % |
|
30.9 % |
|
|
Advanced Materials & Catalysts(2) |
|
26.1 % |
|
25.4 % |
|
|
|
28.5 % |
|
25.7 % |
|
|
Total Adjusted EBITDA Margin(2) |
|
24.4 % |
|
26.8 % |
|
|
|
22.1 % |
|
25.9 % |
|
|
(1) |
Represents GAAP sales for the Advanced Silicas business; Excludes our proportionate 50% share of sales from the |
(2) |
Adjusted EBITDA Margin calculation reflects our proportionate 50% share of sales from the Zeolyst Joint Venture. |
Appendix Table A-4: Adjusted Free Cash Flow |
||||
|
||||
|
|
Six months ended
|
||
|
|
2025 |
|
2024 |
|
|
(in millions) |
||
Net cash provided by operating activities |
|
$ 43.3 |
|
$ 46.4 |
Less: |
|
|
|
|
Purchases of property, plant and equipment(1) |
|
(49.5) |
|
(36.6) |
Free Cash Flow(2) |
|
$ (6.2) |
|
$ 9.8 |
|
|
|
|
|
Adjustments to free cash flow: |
|
|
|
|
Cash paid for debt financing costs |
|
1.0 |
|
4.6 |
Cash paid for costs related to the |
|
2.8 |
|
— |
Adjusted Free Cash Flow(2) |
|
$ (2.4) |
|
$ 14.4 |
|
|
|
|
|
Net cash used in investing activities(3) |
|
$ (90.8) |
|
$ (36.8) |
Net cash used in financing activities |
|
$ (29.4) |
|
$ (14.4) |
(1) |
Excludes the Company's proportionate 50% share of capital expenditures from the Zeolyst Joint Venture. |
(2) |
We define Adjusted Free Cash Flow as net cash provided by operating activities less purchases of property, plant and |
(3) |
Net cash used in investing activities includes purchases of property, plant and equipment, which is also included in our |
Appendix Table A-5: Net Debt Leverage Ratio |
|||
|
|||
|
|
|
|
|
(in millions, except ratios) |
||
Total debt |
$ 866.5 |
|
$ 873.0 |
Less: |
|
|
|
Cash and cash equivalents |
69.6 |
|
83.3 |
Net debt |
$ 796.9 |
|
$ 789.7 |
|
|
|
|
Trailing twelve months: |
|
|
|
Net (loss) income |
$ (13.8) |
|
$ 56.1 |
Adjusted EBITDA(1) |
$ 230.3 |
|
$ 240.1 |
|
|
|
|
Net Debt to Net Income ratio |
NM |
|
14.1x |
Net Debt Leverage ratio |
3.5x |
|
3.3x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1) |
Refer to Appendix Table A-1: Reconciliation of Net Income (Loss) to Adjusted EBITDA for the reconciliation to the most |
View original content to download multimedia:https://www.prnewswire.com/news-releases/ecovyst-reports-second-quarter-2025-results-302523802.html
SOURCE